300601 康泰生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)1.7339.298-1.46215.19413.290
总资产报酬率 ROA (%)1.1205.966-0.95010.64610.035
投入资产回报率 ROIC (%)1.3737.268-1.12712.8458.360

边际利润分析
销售毛利率 (%)83.77784.53884.16672.99089.992
营业利润率 (%)11.87127.288-10.05839.76534.291
息税前利润/营业总收入 (%)12.33226.996-11.38337.78933.213
净利润/营业总收入 (%)13.75624.768-4.20334.59330.037

收益指标分析
经营活动净收益/利润总额(%)138.86996.559-159.565105.54294.242
价值变动净收益/利润总额(%)0.9780.201-1.2182.0655.674
营业外收支净额/利润总额(%)-4.392-0.9146.113-0.903-0.383

偿债能力分析
流动比率 (X)1.6791.9612.2122.8043.044
速动比率 (X)1.3461.6801.9012.4002.795
资产负债率 (%)33.99536.74934.82435.21322.130
带息债务/全部投入资本 (%)16.40618.46217.87020.562--
股东权益/带息债务 (%)489.590423.035437.893369.169-4,519.100
股东权益/负债合计 (%)194.159172.118187.155183.988351.871
利息保障倍数 (X)12.832-601.93216.989-23.326-35.089

营运能力分析
应收账款周转天数 (天)418.575262.999213.998151.4900.000
存货周转天数 (天)769.655502.381643.025272.7550.000